Small Masses Near a BioZorb Marker After DCIS Treatment Were Fat Necrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive.

Small masses detected three years after DCIS treatment were confirmed as fat necrosis during ongoing surveillance.

PubMed CentralRead more →

A New BioZorb-Site Asymmetry After Triple-Negative Breast Cancer Was Fibrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2-negative., triple negative

A new focal asymmetry three years after treatment was confirmed as fibrosis and foreign-body reaction rather than recurrent cancer.

PubMed CentralRead more →

Local Breast Cancer Recurrence Was Found During BioZorb Surveillance

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial right breast tumor: ER-positive, PR-positive, HER2-equivocal. Recurrent right breast tumor: ER-positive, HER2-negative.

Two sites of right-breast recurrence were confirmed three years after lumpectomy, leading to right mastectomy.

PubMed CentralRead more →

A New Mass Near a BioZorb Implant Was a Foreign-Body Reaction

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative.

Follow-up imaging after a benign biopsy showed no mammographic evidence of malignancy.

PubMed CentralRead more →

A BioZorb-Site Density Two Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new density at the lumpectomy site was confirmed as fat necrosis rather than recurrent cancer during ongoing surveillance.

PubMed CentralRead more →

A New Mass Three Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new mass detected three years after treatment was biopsy-proven fat necrosis rather than recurrent cancer.

PubMed CentralRead more →

A Surveillance Asymmetry Near a BioZorb Marker Was Benign Scar and Fat Necrosis

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative.

The new surveillance asymmetry was confirmed as benign fat necrosis, fibrosis, and scar tissue, with follow-up imaging planned.

PubMed CentralRead more →

A Mass Beside a BioZorb Implant Was Fat Necrosis, Not Recurrence

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A 1.8 cm mass detected beside the BioZorb site was confirmed as fat necrosis, with continued imaging follow-up recommended.

PubMed CentralRead more →

Silicone lymphadenopathy after treatment for recurrent triple-negative breast cancer

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative; BRCA1-negative; BRCA2-negative; latest recurrence Ki-67 60%–70%.

At the May 2020 follow-up, biopsies confirmed silicone-related lymph-node changes rather than cancer, and imaging showed no recurrent disease while six-monthly surveillance continued.

PubMed CentralRead more →

Right breast cancer with contralateral axillary lymph-node metastasis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Right breast primary: ER-positive; PR-positive; HER2-negative; Ki-67 70%. Left axillary metastasis: ER-positive; PR-negative; HER2-negative; Ki-67 15%; GATA3-positive.

Metastatic Site: contralateral left axillary lymph nodes

Two years after bilateral surgery, clinical and radiological follow-up showed no metastasis or disease recurrence.

PubMed CentralRead more →

Linda Stokes

Patient Info: Linda Stokes, Female

Biomarkers: germline CDH1 mutation

After breast cancer led to discovery of a CDH1 mutation, Linda Stokes chose bilateral mastectomy and later preventive stomach removal.

A difficult breast-reconstruction infection after breast cancer treatment

Patient Info: Anonymized, Female, 40s

After wide debridement and prolonged antibiotic treatment, the breast and abdominal wounds healed, imaging showed resolution of the subcutaneous infection, and no infection recurrence was seen over three years.

PubMed CentralRead more →

Ductal and lobular carcinoma in situ arising within a fibroadenoma

Patient Info: Anonymized, Female, 40s

Biomarkers: DCIS ER-positive and PR-positive; LCIS E-cadherin-negative.

Lumpectomy achieved tumor-free margins for the in situ disease, and she subsequently completed adjuvant radiation therapy.

PubMed CentralRead more →

Locally advanced male breast cancer associated with a pathogenic ATM variant

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ER 100% positive; PR 100% positive; HER2-negative; Ki-67 30%; germline pathogenic ATM variant c.2921+1G>A.

Two years after diagnosis, he had an ECOG performance status of 0 and remained without signs of breast-cancer relapse or another primary cancer.

PubMed CentralRead more →

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed CentralRead more →

Breast Cancer: Luz's Survivor Story

Patient Info: Luz

Luz described her breast cancer as being in remission after mastectomy, lymph-node surgery, and chemotherapy, and she remained on hormone therapy.

Our Cancer StoriesRead more →

Cherie's Stage 2 Breast Cancer Story After a Second Opinion

Patient Info: Cherie, Female, 50s | Stage II

Cherie described herself as being in remission while continuing hormone therapy. She remained concerned about relapse and used travel and painting to manage anxiety.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Kelly's Patient Story

Patient Info: Kelly, Female, 40s | Stage III

Kelly had Stage III breast cancer diagnosed around 2021, with treatment that included mastectomy, lymphadenectomy, chemotherapy, and radiation therapy; after a treatment change, she was still receiving radiation therapy.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Aurora's Patient Story

Patient Info: Aurora, Female, 40s | Stage III

Aurora was treated for Stage III breast cancer with mastectomy, lymphadenectomy, Cytoxan chemotherapy, and radiation therapy, then moved to chemotherapy alone after the initial plan was not working effectively.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Erika's Patient Story

Patient Info: Erika, Female, 40s | Stage II

As of 2021, Erika was undergoing treatment for Stage II breast cancer and was on targeted therapy after mastectomy, lymphadenectomy, chemotherapy, and targeted therapy.

Our Cancer StoriesRead more →

Stage II HER2-Positive Breast Cancer: Kelsey's Survivor Story

Patient Info: Kelsey, Female, 40s | Stage II

Biomarkers: HER2-positive

Kelsey survived Stage II HER2-positive breast cancer after mastectomy, chemotherapy, and targeted therapy, with recovery supported by nutrition changes, massages, supplements, and support-group connection.

Our Cancer StoriesRead more →

Stage I Breast Cancer: Melissa's Patient Story

Patient Info: Melissa | Stage I

Melissa was in remission and continued hormone therapy while managing fear of recurrence.

Our Cancer StoriesRead more →

Stage I Breast Cancer: Stella's Patient Story

Patient Info: Stella | Stage I

She is in remission after surgery and chemotherapy and remains on hormone therapy.

Our Cancer StoriesRead more →

Stage IV Breast Cancer: Rachael's Patient Story

Patient Info: Rachael | Stage IV

Rachael was living with stage 4 breast cancer after following a plan of mastectomy, chemotherapy, and radiation therapy.

Our Cancer StoriesRead more →